{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:40:14Z","timestamp":1756284014195,"version":"3.44.0"},"reference-count":17,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2025,1,24]]},"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>Overlap syndromes involving myasthenia gravis, myositis and myocarditis are recognised adverse effects of immune checkpoint inhibitors (ICI). We report a similar syndrome of myasthenia gravis and myositis in a patient without prior ICI exposure. Diagnostic tests showed signs of both immune-mediated necrotising myopathy and myasthenia gravis. Symptoms included proximal muscle weakness, ophthalmoplegia, bulbar symptoms and neuromuscular respiratory failure. Initial treatment with glucocorticoids and intravenous immunoglobulin for myositis was partially effective. Significant improvement occurred with rituximab and an acetylcholinesterase inhibitor. Although imaging had not revealed a thymic mass suggestive of thymoma, the patient underwent thymectomy several weeks after recovering from the acute illness. Histopathological examination of the resected tissue confirmed the presence of thymoma. This case illustrates that myasthenia gravis and myositis can spontaneously co-present. Clinicians should consider the possibility that a seemingly atypical presentation of a condition may reflect a more typical presentation of two conditions, such as in this case. In this situation, paraneoplastic causes should be considered.<\/jats:p>","DOI":"10.1136\/bcr-2024-262565","type":"journal-article","created":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T09:45:22Z","timestamp":1739007922000},"page":"e262565","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Global weakness with no clear precipitant: thymoma presenting as a necrotising myositis and myasthenia gravis overlap syndrome"],"prefix":"10.1136","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-6484-6705","authenticated-orcid":false,"given":"Edmund Hugh","family":"Larkin","sequence":"first","affiliation":[{"name":"General Internal Medicine, Whittington Hospital NHS Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6065-9913","authenticated-orcid":false,"given":"Rhys","family":"Thomas","sequence":"additional","affiliation":[{"name":"Rheumatology, Royal Free Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3787-0531","authenticated-orcid":false,"given":"Fernanda","family":"Ruiz","sequence":"additional","affiliation":[{"name":"Neuropathology, University College London, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamir","family":"Malley","sequence":"additional","affiliation":[{"name":"Rheumatology, Royal Free Hospital, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,2,8]]},"reference":[{"key":"2025082701252310000_18.2.e262565.1","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025082701252310000_18.2.e262565.2","doi-asserted-by":"crossref","first-page":"101433","DOI":"10.1016\/j.berh.2019.101433","article-title":"Myalgia in myositis and myopathies","volume":"33","author":"Glaubitz","year":"2019","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025082701252310000_18.2.e262565.3","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s10067-020-05273-3","article-title":"Myositis-specific autoantibodies in adults with idiopathic inflammatory myopathy: correlations with diagnosis and disease activity","volume":"40","author":"Zhao","year":"2021","journal-title":"Clin Rheumatol"},{"key":"2025082701252310000_18.2.e262565.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141443"},{"key":"2025082701252310000_18.2.e262565.5","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/rheumatology\/keac115","article-title":"British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy","volume":"61","author":"Oldroyd","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025082701252310000_18.2.e262565.6","doi-asserted-by":"crossref","first-page":"1110499","DOI":"10.3389\/fimmu.2023.1110499","article-title":"Inflammation and autoimmune myasthenia gravis","volume":"14","author":"Huda","year":"2023","journal-title":"Front Immunol"},{"key":"2025082701252310000_18.2.e262565.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678"},{"key":"2025082701252310000_18.2.e262565.8","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2015-001126"},{"key":"2025082701252310000_18.2.e262565.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602489"},{"key":"2025082701252310000_18.2.e262565.10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11926-022-01052-y","article-title":"Idiopathic Orbital Myositis Revisited","volume":"24","author":"Mombaerts","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"2025082701252310000_18.2.e262565.11","first-page":"303","volume-title":"Handbook of clinical neurology","volume":"160","author":"Juel","year":"2022"},{"key":"2025082701252310000_18.2.e262565.12","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2021-003073"},{"key":"2025082701252310000_18.2.e262565.13","doi-asserted-by":"crossref","first-page":"1051609","DOI":"10.3389\/fimmu.2022.1051609","article-title":"Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis","volume":"13","author":"Zhen","year":"2022","journal-title":"Front Immunol"},{"key":"2025082701252310000_18.2.e262565.14","doi-asserted-by":"crossref","first-page":"1275533","DOI":"10.3389\/fneur.2023.1275533","article-title":"Rituximab treatment in myasthenia gravis","volume":"14","author":"Vesperinas-Castro","year":"2023","journal-title":"Front Neurol"},{"key":"2025082701252310000_18.2.e262565.15","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931"},{"key":"2025082701252310000_18.2.e262565.16","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27118"},{"key":"2025082701252310000_18.2.e262565.17","doi-asserted-by":"crossref","DOI":"10.1136\/bmjresp-2023-002076","article-title":"Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis","volume":"10","author":"Nayebirad","year":"2023","journal-title":"BMJ Open Respir Res"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2024-262565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T08:25:34Z","timestamp":1756283134000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2024-262565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":17,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,8]]},"published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.1136\/bcr-2024-262565"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2024-262565","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}